Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis (CLLS) published its monthly information on share capital and voting rights as of November 30, 2025. The release reports the total number of shares as 100,325,454 and the total number of voting rights as 105,406,812. The announcement lists the listing market as Euronext Growth and the ISIN code as FR0010425595. Contact details for media and investor relations are provided for further information.

News Market Reaction

+3.65%

1 alert

+3.65% News Effect

On the day this news was published, CLLS gained 3.65%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Total shares: 100,325,454 Total voting rights: 105,406,812 Price change 24h: 11.76% +3 more

6 metrics

Total shares 100,325,454 Share capital as of Nov 30, 2025

Total voting rights 105,406,812 Voting rights as of Nov 30, 2025

Price change 24h 11.76% Pre-news daily move

52-week high 5.4796 52-week range context

52-week low 1.1 52-week range context

Trading volume 219,265 Today vs 20-day average 137,917 (1.59x)

Market Reality Check

Price: $4.42 Vol: Volume 219,265 vs 20-day ...

high vol

$4.42 Last Close

Volume Volume 219,265 vs 20-day average 137,917 (relative volume 1.59x) ahead of this routine disclosure. high

Technical Shares traded above the 200-day MA of 2.44, with price at 5.22 before this filing.

Peers on Argus

CLLS was up 11.76% while close peers were mixed: ENGN up 10.95%, KRRO up 1.15%, ...

1 Down

CLLS was up 11.76% while close peers were mixed: ENGN up 10.95%, KRRO up 1.15%, ABEO slightly positive, FDMT flat, and GLUE down 4.5%, indicating stock-specific strength rather than a broad biotech move.

Historical Context

5 past events · Latest: Dec 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 08	Clinical data update	Positive	-2.5%	Updated Phase 1 NATHALI-01 eti-cel data with high ORR and CR rates.
Dec 03	Share capital report	Neutral	+3.6%	Monthly disclosure of total shares and total voting rights as of Nov 30.
Nov 19	Scientific publication	Positive	+7.1%	Nature Communications article on non-viral CssDNA-based gene insertion process.
Nov 07	Earnings and update	Positive	+11.3%	Q3 2025 results with favorable clinical data and strengthened financial position.
Nov 07	Share capital report	Neutral	+1.9%	Monthly share capital and voting rights disclosure as of Oct 31.

Pattern Detected

Recent Cellectis news has mostly seen price moves aligned with the underlying positive or neutral updates, with one notable divergence where strong ASH 2025 data was followed by a price decline.

Recent Company History

Over the last two months, Cellectis issued several clinically and strategically important updates. On Nov 7, 2025, Q3 results and a business update highlighted promising lasme-cel and eti-cel data and stronger finances, with the stock rising 11.29%. A Nature Communications paper on Nov 19, 2025 showcasing a non-viral CssDNA gene-editing process preceded a 7.06% gain. Monthly share capital/voting-rights notices on Oct 31 and Nov 30, 2025 have been neutral disclosures with modest positive reactions, while updated Phase 1 eti-cel data at ASH on Dec 8, 2025 coincided with a -2.53% move.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-07-02

Cellectis has an effective Form F-3 shelf registration dated 2025-07-02, expiring 2028-07-02, with 0 recorded usages in the provided context.

Market Pulse Summary

This announcement provides routine monthly transparency on Cellectis’s capital structure, confirming...

Analysis

This announcement provides routine monthly transparency on Cellectis’s capital structure, confirming 100,325,454 shares and 105,406,812 voting rights as of November 30, 2025 under French regulatory rules. In the past months, the company also reported key clinical and financial developments, so investors may track these share and voting-rights figures alongside potential future financing activity under the existing Form F-3 shelf. Monitoring subsequent clinical milestones and corporate filings remains important.

Key Terms

isin, voting rights

2 terms

isin financial

"Listing market: Euronext Growth ISIN code: FR0010425595"

A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.

voting rights financial

"Total number of voting rights"

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

AI-generated analysis. Not financial advice.

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Dec. 03, 2025 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
11/30/2025	100,325,454	105,406,812

For further information on Cellectis, please contact:     

Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

• Voting_Rights_PR_November_2025_EN

FAQ

What number of shares did Cellectis (CLLS) report on November 30, 2025?

Cellectis reported a total of 100,325,454 shares as of 11/30/2025.

How many voting rights does Cellectis (CLLS) have as of November 30, 2025?

The total number of voting rights was reported as 105,406,812 on 11/30/2025.

Where is Cellectis (CLLS) listed and what is its ISIN code?

Cellectis is listed on Euronext Growth and its ISIN is FR0010425595.

When is the reporting date for the share capital and voting rights figures for Cellectis (CLLS)?

The figures are reported with an effective date of November 30, 2025.

Who can investors contact for more information about Cellectis (CLLS) share capital?

Investor relations contact is Arthur Stril, Chief Financial Officer & Chief Business Officer at investors@cellectis.com.

Where can I find the voting rights attachment for Cellectis (CLLS) November 2025?

The announcement references an attachment titled Voting_Rights_PR_November_2025_EN for detailed information.